Ratings by Wells Fargo (Benjamin Burnett)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/3/2025 | Xenon Pharmaceuticals | XENE | New Coverage | Overweight (N/A) |
38.71 (41.94) |
8.34% | Details | |
| 9/3/2025 | Axsome Therapeutics | AXSM | New Coverage | Overweight (N/A) |
121.28 (162.33) |
33.85% | Details |
